Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Correction: Overexpression of CTEN relates to tumor malignant potential and poor outcomes of adenocarcinoma of the esophagogastric junction.

Aratani K, Komatsu S, Ichikawa D, Ohashi T, Miyamae M, Okajima W, Imamura T, Kiuchi J, Nishibeppu K, Kosuga T, Konishi H, Shiozaki A, Fujiwara H, Okamoto K, Tsuda H, Otsuji E.

Oncotarget. 2019 Oct 1;10(55):5726. doi: 10.18632/oncotarget.27229. eCollection 2019 Oct 1.

2.

Overexpression of CTEN relates to tumor malignant potential and poor outcomes of adenocarcinoma of the esophagogastric junction.

Aratani K, Komatsu S, Ichikawa D, Ohashi T, Miyamae M, Okajima W, Imamura T, Kiuchi J, Nishibeppu K, Kosuga T, Konishi H, Shiozaki A, Fujiwara H, Okamoto K, Tsuda H, Otsuji E.

Oncotarget. 2017 Sep 20;8(48):84112-84122. doi: 10.18632/oncotarget.21109. eCollection 2017 Oct 13. Erratum in: Oncotarget. 2019 Oct 01;10(55):5726.

3.

Adenocarcinoma of the esophagogastric junction in Japan.

Yamamoto M, Baba H, Egashira A, Oki E, Ikebe M, Kakeji Y, Maehara Y.

Hepatogastroenterology. 2008 Jan-Feb;55(81):103-7.

PMID:
18507087
4.

Epidemiology of adenocarcinoma of the esophagogastric junction.

Keeney S, Bauer TL.

Surg Oncol Clin N Am. 2006 Oct;15(4):687-96. Review.

PMID:
17030267
5.

Fibroblast growth factor receptor 2 expression, but not its genetic amplification, is associated with tumor growth and worse survival in esophagogastric junction adenocarcinoma.

Tokunaga R, Imamura Y, Nakamura K, Ishimoto T, Nakagawa S, Miyake K, Nakaji Y, Tsuda Y, Iwatsuki M, Baba Y, Sakamoto Y, Miyamoto Y, Saeki H, Yoshida N, Oki E, Watanabe M, Oda Y, Bass AJ, Maehara Y, Baba H.

Oncotarget. 2016 Apr 12;7(15):19748-61. doi: 10.18632/oncotarget.7782.

6.

Adenocarcinomas of the esophagogastric junction: experiences at a single institution in China.

Zhang H, Wang W, Cheng Y, Song Y, Zhu K, Dang C.

World J Surg Oncol. 2013 Jul 13;11:155. doi: 10.1186/1477-7819-11-155.

7.

Overexpression of EGFR as an Independent Prognostic Factor in Adenocarcinoma of the Esophagogastric Junction.

Aratani K, Komatsu S, Ichikawa D, Ohashi T, Miyamae M, Okajima W, Imamura T, Kiuchi J, Nishibeppu K, Kosuga T, Konishi H, Shiozaki A, Fujiwara H, Okamoto K, Tsuda H, Otsuji E.

Anticancer Res. 2017 Jun;37(6):3129-3135.

PMID:
28551654
8.

[Survival comparison of Siewert II adenocarcinoma of esophagogastric junction between transthoracic and transabdominal approaches:a joint data analysis of thoracic and gastrointestinal surgery].

Yang S, Yuan Y, Hu H, Li R, Liu K, Zhang W, Yang K, Yang Y, Bai D, Chen X, Zhou Z, Chen L.

Zhonghua Wei Chang Wai Ke Za Zhi. 2019 Feb 25;22(2):132-142. Chinese.

PMID:
30799535
9.

Correction: Prorenin receptor acts as a potential molecular target for pancreatic ductal adenocarcinoma diagnosis.

Arundhathi A, Chuang WH, Chen JK, Wang SE, Shyr YM, Chen JY, Liao WN, Chen HW, Teng YM, Pai CC, Wang CH.

Oncotarget. 2019 Jan 11;10(4):558. doi: 10.18632/oncotarget.26597. eCollection 2019 Jan 11.

10.

Erratum: The postoperative complication for adenocarcinoma of esophagogastric junction.

[No authors listed]

J Cancer Res Ther. 2016 Jul-Sep;12(3):1210. doi: 10.4103/0973-1482.197538.

11.

[HER-2 expression and clinical significance in esophagogastric junction adenocarcinoma (Siewert type Ⅱ)].

Luo ZL, Fu MY, Tian D, Shi GD.

Zhonghua Zhong Liu Za Zhi. 2016 Sep 23;38(9):667-71. doi: 10.3760/cma.j.issn.0253-3766.2016.09.006. Chinese.

PMID:
27647398
12.

Correction: Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma.

Zhao T, Ren H, Jia L, Chen J, Xin W, Yan F, Li J, Wang X, Gao S, Qian D, Huang C, Hao J.

Oncotarget. 2019 Sep 17;10(53):5569-5570. doi: 10.18632/oncotarget.27205. eCollection 2019 Sep 17.

13.

[CT in differentiation of cT3 and cT4a Siewert type II esophagogastric junction adenocarcinoma: A comparison study based on UICC/AJCC 8th edition and IGCA 4th edition].

Fu J, Tang L, Li Z, Li X, Zhang Y, Gao S, Sun Y, Ji J.

Zhonghua Wei Chang Wai Ke Za Zhi. 2018 Sep 25;21(9):1013-1018. Chinese.

PMID:
30269321
14.

Comparison of mediastinal lymph node metastases from adenocarcinoma of the esophagogastric junction versus lower esophageal squamous cell carcinoma with involvement of the esophagogastric junction.

Mine S, Watanabe M, Kumagai K, Okamura A, Yuda M, Hayami M, Yamashita K, Imamura Y, Ishizuka N.

Dis Esophagus. 2019 Feb 22. pii: doz002. doi: 10.1093/dote/doz002. [Epub ahead of print]

PMID:
30791046
15.

Overexpression of YWHAZ as an independent prognostic factor in adenocarcinoma of the esophago-gastric junction.

Watanabe N, Komatsu S, Ichikawa D, Miyamae M, Ohashi T, Okajima W, Kosuga T, Konishi H, Shiozaki A, Fujiwara H, Okamoto K, Tsuda H, Otsuji E.

Am J Cancer Res. 2016 Nov 1;6(11):2729-2736. eCollection 2016.

16.

Erratum: Lymph node dissection for Siewert II esophagogastric junction adenocarcinoma: Erratum.

[No authors listed]

Medicine (Baltimore). 2017 Jun 16;96(24):e7316. doi: 10.1097/MD.0000000000007316. eCollection 2017 Jun.

17.

Optimal treatment for Siewert type II and III adenocarcinoma of the esophagogastric junction: A retrospective cohort study with long-term follow-up.

Hosoda K, Yamashita K, Moriya H, Mieno H, Watanabe M.

World J Gastroenterol. 2017 Apr 21;23(15):2723-2730. doi: 10.3748/wjg.v23.i15.2723.

18.

Lymph node metastases of adenocarcinoma of the esophagus and esophagogastric junction.

Zhang X, Watson DI, Jamieson GG.

Chin Med J (Engl). 2007 Dec 20;120(24):2268-70.

PMID:
18167216
20.

[Meta-analysis on relationship between Helicobacter pylori infection and esophagogastric junction adenocarcinoma].

Ma S, Ma Q, Li J, Wei W.

Zhonghua Liu Xing Bing Xue Za Zhi. 2016 Mar;37(3):418-24. doi: 10.3760/cma.j.issn.0254-6450.2016.03.027. Chinese.

PMID:
27005550

Supplemental Content

Support Center